CO4600681A1 - Composicion farmaceutica para la modulacion inmunitaria - Google Patents

Composicion farmaceutica para la modulacion inmunitaria

Info

Publication number
CO4600681A1
CO4600681A1 CO97009092A CO97009092A CO4600681A1 CO 4600681 A1 CO4600681 A1 CO 4600681A1 CO 97009092 A CO97009092 A CO 97009092A CO 97009092 A CO97009092 A CO 97009092A CO 4600681 A1 CO4600681 A1 CO 4600681A1
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
peptide
immunity modulation
adjuvant
treated
Prior art date
Application number
CO97009092A
Other languages
English (en)
Inventor
Walter Schmidt
Max Birnstiel
Peter Steinlein
Michael Buschle
Schweighoffe Tamas
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27215945&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO4600681(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19607044A external-priority patent/DE19607044A1/de
Priority claimed from DE19638313A external-priority patent/DE19638313C2/de
Priority claimed from DE19648687A external-priority patent/DE19648687A1/de
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of CO4600681A1 publication Critical patent/CO4600681A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Composición farmacéutica que contiene al menos un péptido deacción inmunomoduladora junto con un coadyuvante, caracterizada porque el coadyuvante presenta la capacidad de aumentar la fijación del péptido a células del individuo a tratar o la entrada del péptido en la célula y determinar una intensificación de la acción inmunomoduladora del péptido.Composición farmacéutica según la reivindicación 1 caracterizada porque el péptido es un ligando para al menos una molécula de MHC que es expresado por el individuo a tratar.
CO97009092A 1996-02-24 1997-02-20 Composicion farmaceutica para la modulacion inmunitaria CO4600681A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19607044A DE19607044A1 (de) 1996-02-24 1996-02-24 Tumorvakzine und Verfahren zu ihrer Herstellung
DE19638313A DE19638313C2 (de) 1996-09-19 1996-09-19 Pharmazeutische Zusammensetzung für die Immunmodulation
DE19648687A DE19648687A1 (de) 1996-11-25 1996-11-25 Pharmazeutische Zusammensetzung für die Immunmodulation

Publications (1)

Publication Number Publication Date
CO4600681A1 true CO4600681A1 (es) 1998-05-08

Family

ID=27215945

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97009092A CO4600681A1 (es) 1996-02-24 1997-02-20 Composicion farmaceutica para la modulacion inmunitaria

Country Status (35)

Country Link
US (1) US7105162B1 (es)
EP (1) EP0881906B2 (es)
JP (1) JP4184433B2 (es)
KR (1) KR100457647B1 (es)
CN (1) CN1177610C (es)
AR (1) AR005945A1 (es)
AT (1) ATE274350T1 (es)
AU (1) AU722264B2 (es)
BG (1) BG63682B1 (es)
BR (1) BR9707694A (es)
CA (1) CA2243559C (es)
CO (1) CO4600681A1 (es)
CZ (1) CZ295396B6 (es)
DE (1) DE59711873D1 (es)
DK (1) DK0881906T4 (es)
EE (1) EE04481B1 (es)
ES (1) ES2225951T5 (es)
HK (1) HK1017257A1 (es)
HR (1) HRP970100B1 (es)
HU (1) HU224410B1 (es)
ID (1) ID16038A (es)
IL (1) IL125361A (es)
MY (1) MY119276A (es)
NO (1) NO983850L (es)
NZ (1) NZ332020A (es)
PE (1) PE55398A1 (es)
PL (1) PL189413B1 (es)
PT (1) PT881906E (es)
RO (1) RO119344B1 (es)
RS (1) RS50101B (es)
SI (1) SI0881906T2 (es)
SK (1) SK284582B6 (es)
TR (1) TR199801649T2 (es)
TW (1) TW585774B (es)
WO (1) WO1997030721A1 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
ATE365050T1 (de) * 1998-02-25 2007-07-15 Us Gov Sec Army Verwendung von hautpenetrationsförderern und für die zerstörung der oberen hautschichten geeigneten mitteln zur erhöhung der transkutanen immunantwort
AU765260B2 (en) * 1998-04-20 2003-09-11 Torrey Pines Institute For Molecular Studies Topical immunostimulation to induce langerhans cell migration
ES2572834T3 (es) * 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
DE19909503A1 (de) * 1999-03-04 2000-09-07 Boehringer Ingelheim Int Tumorassoziiertes Antigen
US6809179B1 (en) 1999-08-04 2004-10-26 Boehringer Ingelheim International Gmbh Tumor-associated antigen (R11)
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) * 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
AT409762B (de) * 2000-04-13 2002-11-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung von zytokin sekretierenden zellen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
KR20020014459A (ko) * 2000-08-18 2002-02-25 서진호 양이온성 아미노산이 부가된 융합단백질 및 이를 이용한생물공정의 개선방법
JP2004519452A (ja) * 2001-01-05 2004-07-02 インターツェル・アクチェンゲゼルシャフト ポリカチオン性化合物の用途
EP1347776A2 (en) * 2001-01-05 2003-10-01 Intercell Biomedizinische Forschungs- und Entwicklungs AG Anti-inflammatory use of polycationic compounds
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
FR2824326B1 (fr) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
CA2452909A1 (en) * 2001-12-07 2003-06-13 Intercell Ag Immunostimulatory oligodeoxynucleotides
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
JP2005533855A (ja) 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト 病原性ウイルスからの別のリーディングフレームによりコードされる抗原
EP2402026A3 (en) 2002-09-13 2012-04-18 Intercell AG Method for isolating hepatitis C virus peptides
AU2003274011B2 (en) 2002-10-15 2010-03-04 Intercell Ag Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
JP2006520202A (ja) 2003-03-04 2006-09-07 インターツェル・アクチェンゲゼルシャフト ストレプトコッカス・ピオゲネス抗原
ATE485056T1 (de) 2003-03-24 2010-11-15 Intercell Ag Verbesserte impfstoffe
CA2520868A1 (en) 2003-03-31 2004-10-14 Intercell Ag Staphylococcus epidermidis antigens
EP2314719A1 (en) 2003-04-15 2011-04-27 Intercell AG S. pneumoniae antigens
AU2004235952A1 (en) 2003-05-07 2004-11-18 Intercell Ag Streptococcus agalactiae antigens I + II
EP2327720A1 (en) 2003-05-30 2011-06-01 Intercell AG Enterococcus antigens
PL1648502T3 (pl) 2003-07-11 2011-05-31 Intercell Ag Szczepionki przeciwko HCV
EP1722819B1 (en) 2004-03-12 2007-12-26 Intercell AG Method for solubilising peptide mixtures
DE102004038134B4 (de) 2004-08-05 2013-07-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Multivalente Chelatoren zum Modifizieren und Organisieren von Zielmolekülen, Verfahren zu ihrer Herstellung sowie ihre Verwendung
EP2149583B1 (en) 2004-09-24 2015-10-28 Novartis AG Modified VP1-capsid protein of parvovirus B19
CA2583026A1 (en) * 2004-10-29 2006-05-04 Intercell Ag Hcv vaccines for chronic hcv patients
US7785612B2 (en) 2005-04-20 2010-08-31 Taiho Pharmaceutical Co., Ltd. Polyamino acid for use as adjuvant
EP1887084A1 (en) * 2006-08-10 2008-02-13 International Investment and Patents SA Plasmids with immunological action
WO2008031133A2 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
JP2008174490A (ja) * 2007-01-18 2008-07-31 Nitto Denko Corp 抗原性ペプチドを主成分とする薬剤
EP2497779A1 (en) 2007-05-02 2012-09-12 Intercell AG Klebsiella antigens
KR100748265B1 (ko) * 2007-06-15 2007-08-10 (주)성문엔지니어링 공동주택에 배선된 전선의 합선방지구조
EP2511291A3 (en) 2007-06-18 2012-11-07 Intercell AG Chlamydia antigens
US8747861B2 (en) 2007-08-02 2014-06-10 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
CN103083643B (zh) * 2008-03-27 2015-01-07 雀巢产品技术援助有限公司 增加肽、肽模拟物和其他胃肠道转运蛋白底物吸收的方法
AU2009323682A1 (en) 2008-12-03 2010-06-10 Protea Vaccine Technologies Ltd. Glutamyl tRNA synthetase (GtS) fragments
WO2010092176A2 (en) 2009-02-13 2010-08-19 Intercell Ag Nontypable haemophilus influenzae antigens
CN102740882A (zh) * 2009-08-27 2012-10-17 诺华有限公司 含有铝、寡核苷酸和聚阳离子的佐剂
CN102695500A (zh) 2009-11-09 2012-09-26 聚光灯技术合伙有限责任公司 多糖基水凝胶
NZ599527A (en) 2009-11-09 2014-04-30 Spotlight Technology Partners Llc Fragmented hydrogels
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
WO2011101465A1 (en) 2010-02-19 2011-08-25 Intercell Ag Ic31 nanoparticles
CN103517713A (zh) 2011-02-22 2014-01-15 彼昂德瓦克斯医药有限公司 在改善的季节性和大流行性流感疫苗中的多聚体多表位多肽
RU2478399C2 (ru) * 2011-06-16 2013-04-10 Государственное научное учреждение Всероссийский научно-исследовательский институт бруцеллеза и туберкулеза животных Российской академии сельскохозяйственных наук (ГНУ ВНИИБТЖ Россельхозакадемии) Способ получения специфического иммуномодулятора
US20140271723A1 (en) * 2013-03-15 2014-09-18 Saint Louis University Adjuvant compositions and methods of using thereof
IL293135A (en) 2015-05-13 2022-07-01 Agenus Inc A preparation containing at least two different complexes of purified stress protein linked to an antigenic peptide
WO2017159686A1 (ja) * 2016-03-15 2017-09-21 Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 免疫療法のためのモニタリングまたは診断ならびに治療剤の設計
AU2017268822B2 (en) * 2016-05-27 2020-03-26 Etubics Corporation Neoepitope vaccine compositions and methods of use thereof
TW201813664A (zh) 2016-10-11 2018-04-16 賽多利克公司 醫藥
CN107469067B (zh) * 2017-09-05 2018-06-19 浙江大学 一种多肽及其改造体在制备免疫调节药物中的应用
AU2019261451A1 (en) 2018-04-26 2020-12-03 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
CN110870913A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 氨基酸类营养素作为疫苗佐剂的应用以及包含氨基酸营养素作为佐剂的疫苗
CN110870912A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 亚甲蓝类染料作为疫苗佐剂的应用、包含该佐剂的疫苗及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1290141A (es) 1968-05-31 1972-09-20
US4847240A (en) * 1978-01-16 1989-07-11 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US4728639A (en) * 1982-07-27 1988-03-01 University Of Tennessee Research Corporation Type-specific opsonic antibodies evoked with a synthetic peptide of streptococcal M protein conjugated to polylysine without adjuvant
US6022544A (en) * 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US4956273A (en) * 1985-10-24 1990-09-11 Southwest Foundation For Biomedical Research Synthetic peptides and method of use for diagnosis and vaccination for AIDS and ARC
BE1000587A4 (fr) 1986-06-13 1989-02-14 Oncogen Coordinats et procedes en vue d'augmenter la proliferation des lymphocytes b.
EP0346022B1 (en) * 1988-06-10 1996-02-14 United Biomedical, Inc. Peptide fragments of HIV
AU4525589A (en) * 1988-10-27 1990-05-14 Regents Of The University Of Minnesota Liposome immunoadjuvants containing il-2
US5480967A (en) 1990-01-05 1996-01-02 United Biomedical, Inc. HIV-1 core protein fragments
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
WO1993019768A1 (en) 1992-04-03 1993-10-14 The Regents Of The University Of California Self-assembling polynucleotide delivery system
EP0658113B1 (en) 1992-08-31 2004-10-20 Ludwig Institute For Cancer Research Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof
US5571711A (en) 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5409703A (en) * 1993-06-24 1995-04-25 Carrington Laboratories, Inc. Dried hydrogel from hydrophilic-hygroscopic polymer
CZ3000U1 (cs) 1993-07-12 1995-02-22 Kufudakis Alekos Farmaceutický prostředek pro imunomodulační a adjuvantní léčbu
JP2828391B2 (ja) * 1993-10-29 1998-11-25 東燃株式会社 オリゴ糖を表面に有するリポソーム
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
US6001809A (en) * 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
UY24367A1 (es) † 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria

Also Published As

Publication number Publication date
RO119344B1 (ro) 2004-08-30
DK0881906T4 (da) 2009-05-25
IL125361A0 (en) 1999-03-12
EP0881906B1 (de) 2004-08-25
CA2243559C (en) 2011-08-09
KR100457647B1 (ko) 2005-06-20
AU1875997A (en) 1997-09-10
EP0881906B2 (de) 2009-02-04
KR19990082601A (ko) 1999-11-25
JP2000506125A (ja) 2000-05-23
YU6297A (sh) 1999-09-27
AR005945A1 (es) 1999-07-21
SK284582B6 (sk) 2005-07-01
ES2225951T5 (es) 2009-06-15
EP0881906A1 (de) 1998-12-09
TW585774B (en) 2004-05-01
ID16038A (id) 1997-08-28
PE55398A1 (es) 1998-09-22
DK0881906T3 (da) 2004-12-20
EE04481B1 (et) 2005-06-15
MY119276A (en) 2005-04-30
EE9800255A (et) 1999-02-15
TR199801649T2 (xx) 1998-12-21
ATE274350T1 (de) 2004-09-15
NO983850D0 (no) 1998-08-21
SI0881906T2 (sl) 2009-06-30
RS50101B (sr) 2009-01-22
HK1017257A1 (en) 1999-11-19
PT881906E (pt) 2004-10-29
WO1997030721A1 (de) 1997-08-28
BR9707694A (pt) 1999-07-27
DE59711873D1 (de) 2004-09-30
CN1211926A (zh) 1999-03-24
HU224410B1 (hu) 2005-08-29
BG63682B1 (bg) 2002-09-30
CZ268998A3 (cs) 1999-07-14
HUP9901186A3 (en) 2001-01-29
NZ332020A (en) 2000-02-28
CN1177610C (zh) 2004-12-01
HUP9901186A2 (hu) 1999-07-28
HRP970100B1 (en) 2001-04-30
NO983850L (no) 1998-10-21
SI0881906T1 (en) 2004-12-31
AU722264B2 (en) 2000-07-27
JP4184433B2 (ja) 2008-11-19
CZ295396B6 (cs) 2005-08-17
HRP970100A2 (en) 1998-04-30
BG102714A (en) 1999-06-30
SK114598A3 (en) 1999-06-11
PL189413B1 (pl) 2005-08-31
IL125361A (en) 2002-08-14
CA2243559A1 (en) 1997-08-28
US7105162B1 (en) 2006-09-12
PL328455A1 (en) 1999-02-01
ES2225951T3 (es) 2005-03-16

Similar Documents

Publication Publication Date Title
CO4600681A1 (es) Composicion farmaceutica para la modulacion inmunitaria
ES2170223T3 (es) Composicion farmaceutica que contiene hidratos de carbonato de lantano seleccionados.
ATE280826T1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
ES2174895T3 (es) Combinaciones metalicas complejas con contenido en carbenos heterociclicos.
BR9913751A (pt) Uso de uma composição para proteção do tecido, e, método de tratar tecido para aperfeiçoar a sua estabilidade dimensional
ES2191182T3 (es) Bandas con multiples estampaciones.
AR016460A1 (es) Composicion oftalmica para ser administrada como un liquido que se gelifica luego de la instilacion en el ojo
CL2004000675A1 (es) Uso de una combinacion de androgeno de origen biogenico o sintetico y un estrogeno de origen biogenico o sintetico para preparar un medicamento util en el tratamiento del hipogonadismo y enfermedades hipofisis o glandula pituitaria en hombres, para e
BG101139A (en) Heteroatoms-containing cyclopentanopyridyloxazolidinons
ES2082162T3 (es) Procedimiento de incineracion de mezclas de residuos de cualquier origen.
BR0015197A (pt) Copolìmero vinìlico, e, composição
BG103558A (en) Sulphonic acid or sulphonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
DE69311541D1 (de) Kosmetische oder pharmazeutische zusammensetzungen zur topischen anwendung die deacylierten glycerophospholipide enthalten
ATE210149T1 (de) Entzündungshemmende zusammensetzung und methode, in welchen des-tyr dynorphin und analoge benutzt werden
ES2530510T3 (es) Constructos peptídicos sintéticos para el diagnóstico y tratamiento de periodontitis asociada con Porphyromonas gingivalis
TR199802351T2 (xx) Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi.
ES2111762T3 (es) Goma gelan autorreticulada.
TW358027B (en) Topical anti-inflammatory comositions containing piroxicam
ES2190064T3 (es) Procedimiento y dispositivo para la fabricacion de poliuretanos con contenido de cargas.
ES2162238T3 (es) Procedimiento de separacion en el que se utiliza una membrana.
IL90414A0 (en) Combination of angiotensin converting enzyme inhibitors with potassium channel modulators and use thereof in pharmaceuticals
AR015230A1 (es) Composicion cosmetica que contiene un compuesto de actividad estimuladora de la produccion de interleuquina-6, cepa rhodotorula sebr 2002, procedimiento depreparacion de un extracto, composicion obtenida, utilizacion de un compuesto de actividad estimuladora y metodo de tratamiento cosmetico.
DE68911132T2 (de) Hematopoietische kolonien stimulierende faktoren zur verbesserung des lipoprotein/cholesterin-profils.
BR9802803A (pt) ação e composições farmacêuticas contendo os mesmos.
ZA879403B (en) Primary biliary cirrhosis autoantigen